New studies focused on genetic, environmental or lifestyle factors that influence risk.
Ambry to Present New Data Showing That up to 30% of Cancer Risk Carriers Are Missed by Current Testing Guidelines at the 2017 ASCO Meeting
- Meeting: 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
- Institution(s): Beth Israel Deaconess Medical Center, Cambridge, MA, and others
- Lead author(s): Mary Linton Bounetheau Peters
- Major finding: Preliminary results show that 6.6% of unselected pancreatic ductal adenocarcinoma (PDAC) patients carry a germline mutation in a gene known to increase PDAC risk and 4.3% have a mutation in genes not previously linked to PDAC. Existing testing criteria did not identify 30% of carriers. Continued refinement of guidelines is necessary to align genetic testing with inherited PDAC risk.